Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is back in the spotlight on Tuesday, December 16, 2025—not because the story suddenly got simpler, but because it’s at the intersection of three things the market obsessively prices every day: regulatory risk, clinical evidence, and cash runway.
SRPT shares traded around $22 in the U.S. session on Dec. 16, up roughly a couple percent in morning trading. [1] That price level is a reminder of how dramatically sentiment has reset in 2025: Sarepta’s market capitalization now sits in the low single-digit billions (roughly $2–$3B, depending on intraday moves). [2]
So what’s “current” as of Dec. 16? The market is digesting a fresh set of financing moves, the post-warning commercial reality for ELEVIDYS, and a growing pile of analyst revisions that still can’t agree on whether Sarepta is a busted biotech—or a coiled spring.
What’s driving Sarepta stock right now
1) A near-term financing milestone: Sarepta’s convertible notes exchange (closing expected Dec. 18)
One of the newest, most concrete developments investors are tracking is Sarepta’s refinancing / exchange of a large slice of its convertible debt.
Sarepta disclosed it entered privately negotiated exchange agreements to swap approximately $291.4 million of 1.25% convertible senior notes due 2027 into about $291.4 million of 4.875% convertible senior notes due 2030, plus about $31.6 million in cash—with the transaction expected to close on or about Dec. 18, 2025 (subject to customary conditions). [3]
Two details matter for stock-watchers:
- After closing, Sarepta’s aggregate 4.875% 2030 converts would total about $893.4 million (including notes originally issued in August 2025). [4]
- Roughly $158.6 million of the 2027 notes would remain outstanding on unchanged terms. [5]
There’s also a market-structure wrinkle: Sarepta noted the placement agent intended to purchase roughly 691,000 shares in privately negotiated transactions from certain investors participating in the exchange, at a discount to the last reported sale price on Dec. 10, 2025—a factor that can influence near-term trading dynamics. [6]
Bottom line: this isn’t a “cure the disease” headline, but it is a “reduce refinancing pressure and buy time” headline—something markets tend to reward when a biotech’s core product narrative is under stress.
ELEVIDYS remains the center of gravity—and the source of the biggest uncertainty
2) The FDA label update: boxed warning + non-ambulatory use removed
Sarepta’s gene therapy ELEVIDYS (delandistrogene moxeparvovec-rokl) is still the company’s most emotionally and financially consequential asset. It’s also the one that has carried the harshest regulatory headlines in 2025.
In mid-November, the FDA approved updated labeling that includes a boxed warning for the risk of acute serious liver injury and acute liver failure. The update also removed the non-ambulatory indication, restricting use to ambulatory Duchenne muscular dystrophy patients aged 4 and older. [7]
Reuters reported that the agency’s move followed two deaths from acute liver failure in non-ambulatory pediatric patients after treatment. [8] Sarepta’s own announcement similarly described the boxed warning, the label removal for non-ambulatory use, and expanded prescriber guidance (including modified steroid regimens and enhanced monitoring). [9]
This is the heart of the SRPT stock debate right now:
- Bull case: ELEVIDYS is still commercially available for a meaningful segment (ambulatory patients), and safety/monitoring changes plus additional clinical work can stabilize confidence and preserve long-term value. [10]
- Bear case: boxed warnings, restricted labeling, and ongoing scrutiny structurally cap adoption and revenue—and the “next adverse event” risk remains an ever-present overhang. [11]
A possible path to re-opening the non-ambulatory market: ENDEAVOR Cohort 8
3) FDA cleared dosing for ENDEAVOR Cohort 8 (enhanced immunosuppression with sirolimus)
Sarepta is not treating the non-ambulatory label removal as the end of the story.
The company announced the FDA approved dosing in Cohort 8 of the ENDEAVOR study to evaluate an enhanced immunosuppressive regimen that includes sirolimus for non-ambulatory individuals. Sarepta said the cohort is expected to enroll about 25 participants in the U.S., with sirolimus dosed before infusion and continued after infusion as part of an effort to mitigate liver injury risk. [12]
Key design points Sarepta highlighted:
- Primary endpoints include incidence of acute liver injury and micro-dystrophin expression at 12 weeks. [13]
- Sarepta expected to initiate the cohort before year-end, with primary endpoint data collection anticipated in 2H 2026 (pending enrollment). [14]
- Decisions about resuming commercial dosing for non-ambulatory patients would be made with the FDA after reviewing data. [15]
For investors, this is a classic “option value” setup: the cohort doesn’t fix today’s label, but it creates a defined experimental path that could, in a best-case scenario, expand future addressable market again.
Sarepta’s older Duchenne franchise: the ESSENCE study didn’t hit significance—and markets noticed
4) ESSENCE confirmatory study: missed primary endpoint, but Sarepta argues COVID disruption masked treatment effect
Sarepta’s 2025 volatility wasn’t just about ELEVIDYS. It also came from the company’s broader Duchenne portfolio.
In its third-quarter 2025 update, Sarepta said its confirmatory study ESSENCE for AMONDYS 45 and VYONDYS 53 did not achieve statistical significance on its primary endpoint at 96 weeks, but showed positive trends favoring therapy. Sarepta said the long trial period overlapped with the COVID-19 pandemic and that excluding COVID-impacted data changed the observed treatment effect. [16]
Reuters coverage captured how sharply the market reacted to the broader Duchenne pipeline questions, reporting that shares plunged in early November after trial setbacks and a weaker outlook narrative around ELEVIDYS. [17]
Sarepta’s stated plan: meet with the FDA to discuss a path to traditional approval based on totality of evidence, including real-world data. [18]
The Q3 numbers: revenue strength, but the ELEVIDYS disruption is visible in the mix
Sarepta reported total revenue of about $399.4 million in Q3 2025, with net product revenues of $370.0 million comprised of $238.5M from its PMO therapies and $131.5M from ELEVIDYS. [19]
A key commercial reality check: the company’s ELEVIDYS revenue decline year-over-year was linked to its decision to suspend shipments to non-ambulatory patients amid safety concerns earlier in 2025 (as described in analyst writeups summarizing the quarter). [20]
Sarepta also reiterated expectations around 2025 performance in analyst coverage, including continued expectations for significant annual revenue contribution from ELEVIDYS in the ambulatory population—while acknowledging uncertainty tied to market disruption and seasonal dynamics. [21]
Another “current” headline investors saw this month: CEO equity award disclosed
In early December filings coverage, Sarepta disclosed a roughly $12 million equity award to CEO Douglas S. Ingram, split between time-based RSUs and a performance-based component tied to Incentive EBITDA over a period ending Dec. 31, 2027, with the performance award eligible to reach up to 200% of target. [22]
This kind of disclosure typically doesn’t move a biotech on its own. But in a high-scrutiny year, markets often interpret insider compensation structures as a window into board confidence—or at least board intent to retain leadership through turbulence.
Analyst forecasts on Dec. 16, 2025: “Hold” consensus, but wide disagreement on fair value
If you want a single number that summarizes SRPT sentiment, it’s this: the Street can’t agree.
- StockAnalysis lists a consensus “Hold” rating with a price target around $26.23, based on a large analyst set. It also shows Wedbush initiating coverage on Dec. 9, 2025 with a Buy rating and a $32 target. [23]
- MarketBeat similarly shows a Hold consensus and an average target around $33.68, while also showing a very wide spread between the highest and lowest published targets. [24]
- MarketWatch’s published snapshot shows an average recommendation of Hold and an average target price around $20.43. [25]
Why the spread? Because small changes in assumptions create huge valuation differences:
- How durable is ambulatory ELEVIDYS demand under a boxed warning? [26]
- Can Sarepta generate data compelling enough to reopen non-ambulatory use? [27]
- What is the FDA’s tolerance for ambiguity in Duchenne endpoints and confirmatory evidence? [28]
- How much financing/dilution risk remains after debt moves like the December exchange? [29]
The result is a stock where two analysts can look at the same pipeline slide deck and see either “recovery setup” or “falling knife with good PR.”
The 2026 setup: what catalysts matter next for SRPT stock
As of Dec. 16, 2025, the next meaningful checkpoints investors are likely to track include:
- Dec. 18, 2025: expected closing window for the convertible notes exchange (timing subject to closing conditions). [30]
- ENDEAVOR Cohort 8 execution: initiation progress and eventual safety/biomarker readouts, with Sarepta pointing to 2H 2026 timing for primary endpoint data (pending enrollment). [31]
- siRNA platform momentum: Sarepta provided a progress update on SRP-1003 (DM1), with cohort advancement and a $200M milestone payment tied to enrollment targets—plus plans to initiate the final cohort in early 2026. [32]
- Regulatory path for PMO therapies: post-ESSENCE discussions with FDA around conversion from accelerated to traditional approval remain an overhang and a potential catalyst. [33]
The risk reality (because biotechs don’t do “quiet years”)
SRPT is not a “set it and forget it” ticker. The 52-week trading range alone—roughly $10 to $130—tells you this stock trades on narrative shocks, not gentle quarterly drift. [34]
The biggest risks investors continue to price include:
- Further safety events in gene therapy populations (even rare events can trigger major regulatory or commercial shifts). [35]
- Label and access constraints that could permanently reduce the revenue ceiling for ELEVIDYS. [36]
- Regulatory unpredictability around confirmatory evidence in Duchenne, especially after ESSENCE’s primary endpoint miss. [37]
- Financing and dilution pressure typical of late-stage biotech companies when commercial trajectories get revised. [38]
Where Sarepta stock stands on Dec. 16, 2025
Sarepta Therapeutics stock on Dec. 16 is best understood as a company trying to do two difficult things at once:
- Stabilize and defend an approved gene therapy franchise under the harshest form of FDA warning, and
- Build credible routes forward (enhanced immunosuppression trials, continued pipeline progress, and balance-sheet engineering) that can re-expand opportunity over time. [39]
That combination creates a stock with real upside scenarios—but also real cliff risks. The Street’s “Hold” consensus masks that underlying reality: SRPT is less a normal equity and more a bundle of probabilities that get repriced whenever new safety, FDA, or trial data hits the tape. [40]
References
1. stockanalysis.com, 2. stockanalysis.com, 3. www.businesswire.com, 4. www.businesswire.com, 5. www.businesswire.com, 6. www.businesswire.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.businesswire.com, 10. www.businesswire.com, 11. www.reuters.com, 12. www.businesswire.com, 13. www.businesswire.com, 14. www.businesswire.com, 15. www.businesswire.com, 16. www.biospace.com, 17. www.reuters.com, 18. www.biospace.com, 19. www.biospace.com, 20. www.nasdaq.com, 21. www.nasdaq.com, 22. www.investing.com, 23. stockanalysis.com, 24. www.marketbeat.com, 25. www.marketwatch.com, 26. www.reuters.com, 27. www.businesswire.com, 28. www.reuters.com, 29. www.businesswire.com, 30. www.businesswire.com, 31. www.businesswire.com, 32. www.businesswire.com, 33. www.biospace.com, 34. stockanalysis.com, 35. www.reuters.com, 36. www.reuters.com, 37. www.biospace.com, 38. www.businesswire.com, 39. www.businesswire.com, 40. stockanalysis.com
